CRISPR has been on the rise to become a new form of COVID-19 detection. 2 of the common labs include one at the Broad Institute led by Feng Zhang and the other by the University of California Berkeley lead by Jennifer Doudna, who had previously fought over patents for CRISPR. Ever since the discovery of the unique specific cutting ability of Cas endonucleases, many diverse applications have been applied with CRISPR. For detection purposes, the design of specific guide RNAs and PAM sequences allow on-site target of viral sequences to cut a fluorescently tagged to emit fluorescence; hence yielding a positive readout. Zhang named this technique SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKING) using Cas13 while Doudna named it DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter) using Cas12a. Meanwhile, Addgene, a major facilitator of sharing molecular biology reagents, had constructed a library of COVID-19 plasmids and related CRISPR technologies. Approximately 2100 plasmids were shared where among them, 11 of them were applicable with CRISPR. Plasmids from SHERLOCK and DETECTR were also shared to various research labs and institutions around the world.